Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James'' Rating Skew
Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA ) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ: DYN ) with an Outperform rating and $15 price target (68% upside). The analysts bet on the targeted delivery of oligonucleotides improving the therapeutic window of first-generation oligonucleotides. Related: Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle … Full story available on Benzinga.com
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James'' Rating Skew
Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA ) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ: DYN ) with an Outperform rating and $15 price target (68% upside). The analysts bet on the targeted delivery of oligonucleotides improving the therapeutic window of first-generation oligonucleotides. Related: Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle … Full story available on Benzinga.com